Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Finding Study of Sugammadex for Reversal of Neuromuscular Blockade in Caucasian Subjects
NCT00552617Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2005
- Primary completion
- Aug 2006
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of Sugammadex in neuromuscular blockade (NMB) (10 arms), sponsored by Merck & Co. Primary endpoint: Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 at Day 1. Started Sep 2005; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00552617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00552617.